A commonly prescribed cancer and arthritis drug that is sometimes used as an oral abortifacient is facing prescription roadblocks in the wake of the Supreme Court's overturning of Roe v Wade. "It's ...

This approval provides patients with a new generic option for the folate analog metabolic inhibitor, which is used to treat ...

Alembic Pharmaceuticals Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its ...

Credit: Shorla Oncology. Jylamvo is an oral solution formulation of methotrexate. The orange-flavored oral solution is stable at room temperature for 90 days. The Food and Drug Administration (FDA) ...

Quantifying the risk of malignant melanoma from methotrexate use proved difficult in this new study, with the authors calling for larger studies with longer follow-up to guide future practice in the ...

The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis ...

Methotrexate significantly lowers systolic blood pressure in newly diagnosed RA patients compared to sulfasalazine, potentially reducing cardiovascular risk. The study provides prospective comparative ...

Indication(s): Chronic gout in adult patients refractory to conventional therapy. The expanded approval was based on data from the phase 4 MIRROR trial, which evaluated Krystexxa plus methotrexate in ...

Methotrexate is a chemotherapeutic agent used as medical therapy for the treatment of ectopic pregnancy. Although it is most commonly administered intramuscularly, obstetricians may inject the ...

Older patients with chronic kidney disease (CKD) had greater risks for serious adverse events when starting on low-dose methotrexate rather than hydroxychloroquine, a propensity score-matched analysis ...

SHENZHEN, CHINA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 30 July ...